Phio schedules final PH-762 Phase 1b findings and plans Phase 2b in 2027
Company / institutional announcement · Phio Pharmaceuticals
Source published: · Event / reporting date: 2026-11-07
Site published: 2026-11-07 · Updated: 2026-11-07
This source is linked automatically. Choose a question to get started.
What changed
Phio announced a November 7 SITC oral presentation of final Phase 1b findings for intratumoral PH-762, its PD-1-silencing siRNA candidate, in cutaneous carcinomas. The company described tolerability and potential tissue-sparing neoadjuvant use, while stating that additional safety and efficacy studies are needed. A Phase 2b study is planned for the first half of 2027.
Why it may matter
Potential business implication: local siRNA immunotherapy could create development and manufacturing opportunities, but the early clinical announcement does not establish surgical replacement.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections